ADTX Stock Analysis: Buy, Sell, or Hold?
ADTX - Aditxt, Inc. Common Stock
$0.05
-0.01 (-19.97%)
▼
5d:
-56.02%
30d:
-57.38%
90d:
-98.57%
HOLD
MODERATE Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When ADTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
6 traders called ADTX this week
75% bullish • 2 bearish
75% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ADTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ADTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ADTX is currently trading at $0.05, which is considered slightly low relative to its 30-day fair value range of $-0.14 to $0.81.
Technical Outlook: Technically, ADTX is in a downtrend. The price is currently testing key support at $0.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 20.0% recently.
Market Sentiment: ADTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $61.00 (+98128.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADTX is in a downtrend. The price is currently testing key support at $0.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 20.0% recently.
Market Sentiment: ADTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $61.00 (+98128.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$-0.14 -
$0.81
Company Quality Score
44/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-20.0%)
- BULLISH: Trading 98128.7% below Wall St target ($61.00)
- CAUTION: 5-day price weakness (-56.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$-0.14 -
$0.81
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.06
Resistance Level
$0.85
Current Trend
Downtrend
Technical data as of
Jun 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.35
Wall Street Target
$61.00
(+98128.7%)
Revenue Growth (YoY)
1094.4%
Share & Embed Analysis
Last updated: June 08, 2026 12:51 PM ET
Data refreshes hourly during market hours. Next update: 1:51 PM
Data refreshes hourly during market hours. Next update: 1:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADTX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Financial Lp Hrt
SELL
11982 shares
2026-04-22
Financial Lp Hrt
BUY
72912 shares
2026-04-21
Brian Michael Brady
SELL
2025-12-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 50 HOLD |
